Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
JMKX003142 Injection in healthy Chinese adults
NCT06344533Phase 1Not yet recruiting
- Sponsor
- Jemincare
- Start
- Apr 2024
- Primary completion
- Jan 2025
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, randomised, double-blind trial in autosomal dominant polycystic kidney disease (ADPKD) and renal edema comparing JMKX003142 Injection with Placebo (2 arms). Primary endpoints: Number of the Adverse Events that are related to the single dose treatment at Day 7 and Number of the Adverse Events that are related to the multiple dose treatment at Day 12. Planned start Apr 2024; status: not yet recruiting.
02
Drugs
JMKX003142
03
Conditions
autosomal dominant polycystic kidney disease (ADPKD)renal edema
Beyond the preview
Go deeper on NCT06344533.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06344533.